ClinicalTrials.gg
Status unknownNCT02576301AMLUpdated Jun 4, 2018

Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS

A Phase 1/2 interventional study of Phase 1 - OXi4503 and Phase 1 - OXi4503 + cytarabine in Acute Myelogenous Leukemia and Myelodysplastic Syndromes, sponsored by Mateon Therapeutics. Status unknown at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-06-04.

Sponsored by Mateon Therapeutics · Phase 1/2, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Sep 2017), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,138 studies in Leukemia, Myeloid, Acute with a site in United States — 309 open to participants now, 463 under way, 24 of them phase 3. Leukemia, Myeloid, Acute · United States.

Planned enrollment
310th of 1,908
105 · median 35
Started
2015
with 105 others
Phase 1/2
306 of 2,138
47 open now
Registered
1,210th of 2,138
by date

Among the 2,138 studies in Leukemia, Myeloid, Acute with a site in United States, this one is the 310th largest by planned enrollment of the 1,908 interventional ones that give a count, is one of 106 that started in 2015, is one of 306 in phase 1/2, and was the 1,210th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

309 of the 2,138 studies in Leukemia, Myeloid, Acute with a site in United States are open now. Recruiting first, the newest first:

304 more — sign in →

All 309 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,138 studies in Leukemia, Myeloid, Acute with a site in United States, or all of them as a file.
02

Study summary

Phase 1 will investigate maximum tolerated dose of OXi4503 as a single agent and in combination with intermediate-dose cytarabine in subjects with relapsed/refractory AML or MDS.

Phase 2 will investigate overall response rate of OXi4503 in combination with intermediate-dose cytarabine in 1) subjects with MDS after failure of 1 prior hypomethylating agent (Arm A) and 2) subjects with relapsed and refractory AML after treatment failure of up to 1 prior chemotherapy regimen (Arm B).

Read the detailed description

Phase 1 dose escalation component will assess the safety, PK/PD, and preliminary efficacy of OXi4503 as a single agent in subjects with relapsed/refractory AML and MDS, and the safety and PK/PD of the combination of OXi4503 with intermediate-dose cytarabine in subjects with AML/MDS.

Phase 2 will assess the preliminary efficacy of the OXi4503+cytarabine combination in 2 cohorts.

03

Conditions studied

  • Acute Myelogenous Leukemia
  • Myelodysplastic Syndromes

Keywords

  • AML
  • MDS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide
  2. ≥ 18 years of age
  3. Phase 1 (dose escalation) subjects must have either:

    • AML that has failed to achieve complete remission or morphologic complete remission or
    • MDS - Marrow blasts must be > 5% and disease failed at least 1 prior hypomethylating agent
  4. Phase 2 (expansion) subjects must have either MDS or AML
  5. performance status 0, 1, or 2
  6. Total ≤ 2
  7. Serum (AST) and alanine aminotransferase (ALT) levels ≤ 2.5 times (ULN)
  8. Serum creatinine \< 2.5 times ULN
  9. (PT)/international normalized ratio and (PTT) in normal range ± 25%
  10. Women of
  11. Males with female partners of child-bearing potential must agree to use physician-approved methods

Exclusion criteria

Exclusion Criteria:

  1. Acute promyelocytic leukemia
  2. Absolute peripheral blood myeloblast count greater than 20,000/mm3
  3. Uncontrolled hypertension
  4. History of congenital long syndrome or torsades de pointes
  5. Pathologic bradycardia or heart block
  6. Prolonged baseline QTc
  7. Hiistory of ventricular arrhythmia
  8. Myocardial infarction and/or new ST elevation
  9. Any history of hemorrhagic stroke
  10. Symptomatic congestive heart failure
  11. Major hemorrhagic event within 28 days
  12. Suggestive central nervous system involvement with leukemia
  13. Any open wound
  14. Pregnant and nursing subjects are excluded
  15. Treatment with any anticancer therapy
  16. Treatment with colchicine is excluded.
  17. Psychiatric disorders that would interfere with consent
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
105 participants (estimated)

Study arms

  • Experimental
    Phase 2 AML

    OXi4503 at MTD plus cytarabine 1g/m2/day

    Drug: Phase 2 - OXi4503 + cytarabine

  • Experimental
    Phase 2 MDS

    OXi4503 at MTD plus cytarabine 1g/m2/day

    Drug: Phase 2 - OXi4503 + cytarabine

  • Experimental
    OXi4503 dose escalation

    MTD for OXi4503 will be determined

    Drug: Phase 1 - OXi4503

  • Experimental
    OXi4503 + cytarabine dose escalation

    MTD of the combination of OXi4503 + cytarbine will be determined

    Drug: Phase 1 - OXi4503 + cytarabine

Interventions

  • DrugOxi 4503Studies of Oxi 4503Oxi 4503 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Determination of MTD of OXi4503

    Also known as: CA1P, combretastatin A1-diphosphate

  • DrugPhase 1 - OXi4503 + cytarabine

    Drug page: Oxi 4503Studies of Oxi 4503Oxi 4503 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Determination of MTD of the combination of OXi4503 + cytarabine

    Also known as: CA1P, combretastatin A1-diphosphate

  • DrugPhase 2 - OXi4503 + cytarabine

    Drug page: Oxi 4503Studies of Oxi 4503Oxi 4503 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Safety and efficacy of the combination of OXi4503 + cytarabine in subjects with AML

    Also known as: CA1P, combretastatin A1-diphosphate

  • DrugPhase 2 - OXi4503 + cytarabine

    Drug page: Oxi 4503Studies of Oxi 4503Oxi 4503 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Safety and efficacy of the combination of OXi4503 + cytarabine in subjects with MDS

    Also known as: CA1P, combretastatin A1-diphosphate

06

What researchers measure

Primary outcomes

  1. Phase 1b:MTD of OXi4503 as a single agent and in combination with intermediate-dose cytarabine in subjects with relapsed/refractory AML or MDS

    Time frame: 1 year

  2. Phase 2: Overall response rate of OXi4503 in combination with intermediate-dose cytarabine in subjects with MDS after failure of 1 prior hypomethylating agent (Arm A), and subjects with relapsed and refractory AML after treatment failure of up

    Time frame: 2 years

07

Study locations

4 of 4 sites recruiting
  • David Geffen School of Medicine at UCLA
    Los Angeles, California 90095, United States
    Recruiting
  • University of Florida
    Gainesville, Florida 32610, United States
    Recruiting
    • Christina Cline, RN · Contactclcline@ufl.edu · 352-273-6840
    • Christopher Cogle R Cogle, MD · Principal investigator
  • University of Miami Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
    Recruiting
    • Yvonne Dinh · Contacty.dinh@med.miami.edu · 305-243-9899
    • Justin Watts, MD · Principal investigator
  • University of Kansas Cancer Center and Medical Pavilion
    Westwood, Kansas 66205, United States
    Recruiting
    • Michelle Cairns, MA · Contactmcairns3@kumc.edu · 913-945-7547
    • Tara Lin, MD · Principal investigator
08

References and documents

Publications

  • Johnson SP, Ogunlade O, Lythgoe MF, Beard P, Pedley RB. Longitudinal Photoacoustic Imaging of the Pharmacodynamic Effect of Vascular Targeted Therapy on Tumors. Clin Cancer Res. 2019 Dec 15;25(24):7436-7447. doi: 10.1158/1078-0432.CCR-19-0360. Epub 2019 Sep 24. PubMed 31551349 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2015, a primary completion of Oct 2019 and a completion of Oct 2020. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2015
First posted
Oct 15, 2015
Start
Oct 2015
Primary completionEst.
Oct 2019
CompletionEst.
Oct 2020
Last update
Jun 4, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02576301
Lead sponsor
Mateon Therapeutics
Responsible party
Sponsor
First posted
Oct 15, 2015
Start date
Oct 2015
Primary completion
Oct 2019 (estimated)
Completion
Oct 2020 (estimated)
Last update
Jun 4, 2018

Study contacts

Rachel Couchenour
Contact
650-635-7000

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxi 4503

Start the discussion